Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.
作者信息
Fizazi Karim, Azad Arun A, Matsubara Nobuaki, Carles Joan, Fay Andre P, De Giorgi Ugo, Joung Jae Young, Fong Peter C C, Voog Eric, Jones Robert J, Shore Neal D, Dunshee Curtis, Zschäbitz Stefanie, Oldenburg Jan, Ye Dingwei, Lin Xun, Healy Cynthia G, Di Santo Nicola, Laird A Douglas, Zohren Fabian, Agarwal Neeraj
机构信息
aInstitut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
bPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
出版信息
Future Oncol. 2025 Mar;21(6):637-652. doi: 10.1080/14796694.2025.2449754. Epub 2025 Jan 30.
Abstract
摘要
相似文献
1
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.他拉唑帕尼联合恩杂鲁胺对比安慰剂联合恩杂鲁胺用于晚期前列腺癌患者及特定DNA修复基因的变化：TALAPRO-2研究结果的通俗易懂总结
Future Oncol. 2025 Mar;21(6):637-652. doi: 10.1080/14796694.2025.2449754. Epub 2025 Jan 30.
2
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.TALAPRO-2 研究结果的简明报告：他拉唑帕尼联合恩扎卢胺对比安慰剂联合恩扎卢胺用于晚期前列腺癌患者。
Future Oncol. 2024;20(29):2123-2135. doi: 10.1080/14796694.2024.2362108. Epub 2024 Jul 12.
3
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.在转移性去势抵抗性前列腺癌且伴有同源重组修复基因改变的男性患者中，一线他拉唑帕尼联合恩杂鲁胺对比安慰剂联合恩杂鲁胺：来自随机、双盲、安慰剂对照3期TALAPRO-2试验的患者报告结局
Lancet Oncol. 2025 Apr;26(4):481-490. doi: 10.1016/S1470-2045(25)00031-2.
4
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.一线他拉唑帕尼联合恩杂鲁胺对比安慰剂联合恩杂鲁胺用于转移性去势抵抗性前列腺癌：来自随机、双盲、安慰剂对照3期TALAPRO-2试验的患者报告结局
Lancet Oncol. 2025 Apr;26(4):470-480. doi: 10.1016/S1470-2045(25)00030-0.
5
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer.TALAPRO-2研究设计的通俗概述：该研究比较了他拉唑帕尼与恩杂鲁胺联合用药和恩杂鲁胺与安慰剂联合用药对转移性去势抵抗性前列腺癌男性患者的疗效。
Future Oncol. 2022 Sep;18(27):2979-2986. doi: 10.2217/fon-2022-0389. Epub 2022 Aug 11.
6
The TALAPRO-3 study design: a plain language summary.TALAPRO-3 研究设计：通俗易懂的概述。
Future Oncol. 2024;20(30):2225-2231. doi: 10.1080/14796694.2024.2363131. Epub 2024 Jul 24.
7
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis.他拉唑帕利联合恩杂鲁胺对比安慰剂联合恩杂鲁胺作为转移性去势抵抗性前列腺癌患者一线治疗的3期研究：TALAPRO-2日本亚组分析
Cancer Med. 2025 Jan;14(1):e70333. doi: 10.1002/cam4.70333.
8
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.泰拉唑帕尼联合恩扎卢胺治疗一线转移性去势抵抗性前列腺癌（TALAPRO-2）：一项随机、安慰剂对照、III 期临床试验。
Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4.
9
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.他拉唑帕利联合恩扎卢胺治疗转移性去势抵抗性前列腺癌：来自随机、安慰剂对照、III 期 TALAPRO-2 研究的安全性分析。
Eur J Cancer. 2024 Dec;213:115078. doi: 10.1016/j.ejca.2024.115078. Epub 2024 Oct 20.
10
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.一线 talazoparib 联合恩扎卢胺治疗 HRR 缺陷转移性去势抵抗性前列腺癌：III 期 TALAPRO-2 试验。
Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4.
Zotero 插件